Pfizer Inc. $PFE Shares Bought by Quintet Private Bank Europe S.A.

Quintet Private Bank Europe S.A. grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 40.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 684,746 shares of the biopharmaceutical company’s stock after purchasing an additional 197,811 shares during the quarter. Pfizer makes up 0.9% of Quintet Private Bank Europe S.A.’s portfolio, making the stock its 26th largest holding. Quintet Private Bank Europe S.A.’s holdings in Pfizer were worth $19,529,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in PFE. BlackRock Inc. increased its stake in shares of Pfizer by 6.3% in the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after purchasing an additional 31,412,883 shares during the period. State Street Corp grew its holdings in Pfizer by 0.5% in the 4th quarter. State Street Corp now owns 300,445,164 shares of the biopharmaceutical company’s stock worth $7,481,085,000 after buying an additional 1,357,756 shares in the last quarter. Bank of New York Mellon Corp increased its position in Pfizer by 11.1% in the 1st quarter. Bank of New York Mellon Corp now owns 53,879,900 shares of the biopharmaceutical company’s stock valued at $1,512,948,000 after acquiring an additional 5,364,929 shares during the period. Bank of America Corp DE bought a new stake in Pfizer during the 2nd quarter valued at $1,049,602,000. Finally, Dimensional Fund Advisors LP boosted its position in Pfizer by 0.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 36,422,799 shares of the biopharmaceutical company’s stock worth $1,022,606,000 after acquiring an additional 293,029 shares during the period. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Scotiabank lifted their price objective on shares of Pfizer from $30.00 to $33.00 and gave the company an “outperform” rating in a research note on Tuesday. Cantor Fitzgerald raised their target price on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Thursday. Weiss Ratings upgraded shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Bank of America decreased their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating for the company in a report on Friday, July 10th. Finally, JPMorgan Chase & Co. dropped their target price on Pfizer from $30.00 to $28.00 and set a “neutral” rating on the stock in a report on Wednesday, July 8th. Five analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Hold” and a consensus target price of $28.61.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved Pfizer’s TUKYSA regimen, in combination with trastuzumab and pertuzumab, as a front-line maintenance treatment for adults with HER2-positive metastatic breast cancer. The expanded indication could increase TUKYSA’s addressable market and support oncology revenue growth. Pfizer’s TUKYSA Regimen Receives FDA Approval
• Positive Sentiment: Pfizer reported positive Phase 3 results for LITFULO in nonsegmental vitiligo, with meaningful facial and total-body repigmentation and favorable tolerability. Planned regulatory submissions could broaden the drug’s commercial opportunity and strengthen Pfizer’s immunology pipeline. Pfizer Posted Positive Phase 3 Vitiligo Results
• Neutral Sentiment: Cantor Fitzgerald raised its Pfizer price target from $27 to $28 but kept a neutral rating, implying limited upside at recent trading levels. Cantor Fitzgerald Raises Pfizer Price Target
• Neutral Sentiment: Pfizer declared its regular $0.43 quarterly dividend, equal to $1.72 annually and a yield of roughly 6%. The payout may attract income-focused investors, although the announcement itself does not change the company’s underlying earnings outlook. Pfizer Declares Fourth-Quarter 2026 Dividend
• Negative Sentiment: Analysts and financial commentary continue to flag risks behind Pfizer’s low valuation and high dividend yield, including a previously frozen payout, elevated debt, a multibillion-dollar write-down, and a reported payout ratio above earnings. These factors raise questions about long-term dividend reliability. Pfizer’s Yield and Dividend Risks
• Negative Sentiment: Pfizer plans to cut approximately 330 jobs at its Sicily, Italy, facility, highlighting ongoing cost pressure and restructuring needs. Investors may view the reductions as evidence of continued operational challenges despite Pfizer’s cost-cutting program. Pfizer to Cut Around 330 Jobs in Italy

Pfizer Price Performance

Shares of NYSE PFE traded down $0.26 during mid-day trading on Thursday, reaching $27.74. The company had a trading volume of 11,910,174 shares, compared to its average volume of 40,384,527. The company has a 50-day moving average price of $27.56 and a two-hundred day moving average price of $26.48. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The stock has a market cap of $158.09 billion, a PE ratio of 36.51, a P/E/G ratio of 1.85 and a beta of 0.32. Pfizer Inc. has a 1-year low of $23.62 and a 1-year high of $29.21.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.77 EPS for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. The company had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The business’s quarterly revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the firm earned $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts anticipate that Pfizer Inc. will post 2.98 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Investors of record on Friday, November 6th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, November 6th. This represents a $1.72 dividend on an annualized basis and a yield of 6.2%. Pfizer’s dividend payout ratio (DPR) is currently 226.32%.

About Pfizer

Pfizer Inc (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis.